Article: Clinical Use of Extended-Release Injectable Naltrexone in the Treatment of Opioid Use Disorder: A Brief Guide.

“A diagnosis of opioid use disorder continues to carry significant social bias, which affects both the individuals who receive the diagnosis and the health care professionals to whom such individuals may turn for care.”

“To review the options available for the treatment of opioid use disorder, the Substance Abuse and Mental Health Services Administration (SAMHSA) and the National Institute on Drug Abuse (NIDA) jointly convened the Consensus Panel on New Pharmacotherapies for Opioid Use Disorders and Related Comorbidities . Composed of experts in research, clinical care, medical education, and public policy, the panel reviewed current evidence on the effectiveness of available medications for the treatment of an opioid use disorder and developed a guidance for clinical practice.5 The panel’s guidance is presented in this document.”

To read the full guide, click here: http://store.samhsa.gov/shin/content/SMA14-4892/SMA14-4892.pdf